Efficacy of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort

Table 4 Glucose, renal function and body weight variation after 6 months of treatment in the sodium-glucose cotransporter-2 inhibitor and control groups, n (%)

Variables	SGLT2i group (n = 387)	Control group (n = 774)	P value
FBG (mmol/L)	7.83 ± 1.62	7.94 ± 1.90	0.769
Variation of FBG (mmol/L)	-0.13 (-0.75, 0.56)	-0.02 (-0.73, 0.64)	0.642
2hPBG (mmol/L)	8.83 ± 2.07	8.87 ± 2.21	0.951
Variation of 2hPBG (mmol/L)	0.17 (-0.90, 0.92)	-0.01 (-1.00, 0.83)	0.623
HbA1c (%)	6.86 ± 1.00	6.72 ± 1.06	0.004
Variation of HbA1c (%)	-0.00 ± 0.81	0.07 ± 0.67	0.219
UACR (mg/g)	89.18 ± 285.30	84.57 ± 423.05	0.001
Variation of UACR (mg/g)	-20.61 ± 283.92	12.01 ± 156.68	0.327
Logarithm of the variation of UACR	-0.02 ± 0.71	0.01 ± 0.91	0.482
eGFR (mL/min/1.73 m2)	86.22 ± 19.04	84.60 ± 18.91	0.297
Variation of eGFR (mL/min/1.73 m2)	-1.01 ± 10.44	0.25 ± 10.74	0.068
Body weight (kg)	72.23 ± 12.31	71.35 ± 12.64	0.479
Variation of body weight (kg)	-0.59 ± 3.83	-0.03 ± 4.07	0.010
BMI (kg/m2)	25.31 ± 3.35	25.15 ± 3.46	0.461
Variation of BMI (kg/m2)	-0.21 ± 1.40	-0.03 ± 1.55	0.013
UACR grades
< 30 mg/g	135 (69.59)	240 (81.63)	0.009
30-300 mg/g	13 (6.70)	12 (4.08)
> 300 mg/g	46 (23.71)	42 (14.29)
Renal composite outcome	4 (1.03)	2 (0.26)	0.169
BMI grades
18-24 kg/m2	4 (1.26)	5 (1.04)	0.682
24-28 kg/m2	105 (33.02)	173 (36.12)
28-35 kg/m2	154 (48.43)	211 (44.05)
> 35 kg/m2	55 (17.30)	90 (18.79)

FBG: Fasting blood glucose; PBG: Prandial blood glucose; HbA_1c: Glycosylated hemoglobin; UACR: Urinary albumin-creatinine ratio; eGFR: Estimated glomerular filtration rate; BMI: Body mass index; SGLT2i: Sodium-glucose cotransporter-2 inhibitor.